Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 1096
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M95396F7824EN
Leaflet:

Download PDF Leaflet

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015’, provides an overview of the Multiple Myeloma (Kahler Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Multiple Myeloma (Kahler Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Multiple Myeloma (Kahler Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Multiple Myeloma (Kahler Disease) Overview
Therapeutics Development
Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies
Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes
Multiple Myeloma (Kahler Disease) - Pipeline Products Glance
Multiple Myeloma (Kahler Disease) - Products under Development by Companies
Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
Drug Profiles
Multiple Myeloma (Kahler Disease) - Recent Pipeline Updates
Multiple Myeloma (Kahler Disease) - Dormant Projects 1026
Multiple Myeloma (Kahler Disease) - Discontinued Products 1046
Multiple Myeloma (Kahler Disease) - Product Development Milestones 1051
Appendix 1065

LIST OF TABLES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2015
Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Advancell, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Affimed Therapeutics AG, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corporation, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals‚ Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by APO-T B.V., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by AvidBiotics Corp., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Axelar AB, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by BioInvent International AB, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by BioLineRx, Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Bluebird bio, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corporation, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis S.A., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by ChemoCentryx, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Compugen Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by ConverGene, LLC, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Curis, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by DARA BioSciences, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime B.V., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Fortress Biotech, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science s.r.l., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology, LLC., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Immunocore Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Immunomic Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corporation, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva SAS, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corporation, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Kancer Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Kezar Life Sciences, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by MandalMed, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune, LLC, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Medivation, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co., Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Merus B.V., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Mirna Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Modulation Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by MolMed S.p.A., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co., Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Panacela Labs, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Patrys Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar, S.A., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Pono Pharma, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Progenra, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by ProMIS Neurosciences Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Quest PharmaTech Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Selexys Pharmaceuticals Corporation, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Sigma-Tau S.p.A., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by TG Therapeutics, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Verastem, Inc., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Virocan Therapeutics Private Limited, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd., H2 2015
Multiple Myeloma (Kahler Disease) - Pipeline by Zyngenia, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Multiple Myeloma (Kahler Disease) Therapeutics - Recent Pipeline Updates, H2 2015
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2015 1056
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H2 2015 1057
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H2 2015 1058
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H2 2015 1059
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H2 2015 1060
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H2 2015 1061
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H2 2015 1062
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H2 2015 1063
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H2 2015 1064
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H2 2015 1065
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H2 2015 1066
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H2 2015 1067
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H2 2015 1068
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H2 2015 1069
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H2 2015 1070
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H2 2015 1071
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H2 2015 1072
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H2 2015 1073
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H2 2015 1074
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H2 2015 1075
Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2015 1076
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H2 2015 1077
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H2 2015 1078
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H2 2015 1079
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H2 2015 1080

LIST OF FIGURES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2015
Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
AB Science SA
AbbVie Inc.
Ablynx NV
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Adaptimmune Limited
Advancell
Affimed Therapeutics AG
Altor BioScience Corporation
Amgen Inc.
Anthera Pharmaceuticals‚ Inc.
APIM Therapeutics AS
APO-T B.V.
Arcarios BV
Arno Therapeutics, Inc.
Array BioPharma Inc.
Arvinas, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Atara Biotherapeutics, Inc.
Aurigene Discovery Technologies Limited
AvidBiotics Corp.
Axelar AB
Bayer AG
Bellicum Pharmaceuticals, Inc.
BioInvent International AB
BioLineRx, Ltd.
Biotest AG
Bluebird bio, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cellectar Biosciences, Inc.
Cellectis S.A.
Cellerant Therapeutics, Inc.
Celleron Therapeutics Limited
Celyad SA
ChemoCentryx, Inc.
Chong Kun Dang Pharmaceutical Corp.
Cleave Biosciences
Compugen Ltd.
Constellation Pharmaceuticals, Inc.
ConverGene, LLC
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
DARA BioSciences, Inc.
DC Prime B.V.
Dicerna Pharmaceuticals, Inc.
Eli Lilly and Company
Enceladus Pharmaceuticals BV
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Fortress Biotech, Inc.
Gamida Cell Ltd.
Genenta Science s.r.l.
GlaxoSmithKline Plc
Gliknik, Inc.
Hutchison MediPharma Limited
IGF Oncology, LLC.
Immunocore Limited
Immunomedics, Inc.
Immunomic Therapeutics, Inc.
Incyte Corporation
Inflection Biosciences Limited
Inventiva SAS
Jasco Pharmaceuticals, LLC.
Johnson & Johnson
JW Pharmaceutical Corporation
KaloBios Pharmaceuticals, Inc.
Kancer Limited
Kancera AB
Karyopharm Therapeutics, Inc.
Kezar Life Sciences, Inc.
MandalMed, Inc.
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merus B.V.
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Modulation Therapeutics, Inc.
Molecular Templates Inc.
MolMed S.p.A.
MorphoSys AG
NantKwest, Inc.
Nippon Kayaku Co., Ltd.
Nordic Nanovector ASA
Novartis AG
Noxxon Pharma AG
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
OncoPep Inc.
Oncopeptides AB
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
OXIS International, Inc.
Panacela Labs, Inc.
Patrys Limited
Peptinov SAS
Pfizer Inc.
Pharma Mar, S.A.
Phylogica Limited
Polyphor Ltd.
Pono Pharma
Prescient Therapeutics Limited
Progenra, Inc.
ProMIS Neurosciences Inc.
Quest PharmaTech Inc.
Rhizen Pharmaceuticals S.A.
Sanofi
Selexys Pharmaceuticals Corporation
Sellas Inc.
Selvita SA
Senhwa Biosciences, Inc.
Sigma-Tau S.p.A.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Sphaera Pharma Pvt. Ltd.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synta Pharmaceuticals Corp.
Taiho Pharmaceutical Co., Ltd.
Targazyme, Inc.
Teva Pharmaceutical Industries Limited
TG Therapeutics, Inc.
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
Transgene Biotek Limited
Vaccibody AS
Vaxil Bio Therapeutics Ltd.
Verastem, Inc.
Vichem Chemie Research Ltd.
Virocan Therapeutics Private Limited
Vivolux AB
XTL Biopharmaceuticals Ltd.
Zyngenia, Inc.
Skip to top


Ask Your Question

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: